ArticleBMC cancer2025
Analysis of FNDC1 as a diagnostic marker and potential therapeutic target for ovarian serous cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFibronectin type III domain containing 1 (FNDC1) is a member of fibronectin type III domain protein family, which is known to play an important role in the metastasis of some cancers. However, it has not been reported about the relationship between FNDC1 and ovarian serous cancer.
methodsFirstly, we investigated the expression of FNDC1 in various cancer types, and analyzed its diagnostic value and potential role in ovarian serous cancer using TCGA database. Subsequently, a series of bioinformatics methods were used to explore the potential oncogenic effects of FNDC1, including the relationship between FNDC1 expression and immune cell infiltration and immune checkpoint molecules, protein-protein interaction network, gene ontology and Kyoto Encyclopedia of Genes and Genomes analysis, gene set enrichment analysis, and toxicity analysis. Finally, the results were further verified by cell function experiments.
resultsFNDC1 was highly expressed in ovarian serous cancer, which was further verified in cell line, indicating that it might be as a diagnostic marker of ovarian serous cancer. In addition, the expression of FNDC1 and TNFSF4, an immune checkpoint molecule, showed a strong positive correlation, and both them were involved in the same signaling pathway, indicating that they might jointly affect T-cell responses in ovarian serous cancer. Moreover, this effect might be inhibited by austocystin D.
conclusionFNDC1 was a potential diagnostic marker, prognostic indicator, and target for the treatment of ovarian serous cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.